All News
FDA ApprovalApril 11, 2026
Anti-Amyloid Revolution in Alzheimer's: Lecanemab and Donanemab Receive FDA Approval
Landmark in Alzheimer's treatment: Two new anti-amyloid antibody drugs receive FDA approval. Slowing cognitive decline by 27-35%.
The most important development in Alzheimer's disease in the past 20 years. Lecanemab (Leqembi®) and Donanemab (Kisunla®) received FDA approval.
Lecanemab: 27% slowing of cognitive decline (CLARITY AD, NEJM 2023). Donanemab: 35% slowing (TRAILBLAZER-ALZ 2, JAMA 2023), with 68% of patients achieving amyloid negativity.
Both carry ARIA risk requiring regular MRI monitoring.
Source: New England Journal of Medicine / JAMA